5-MeO-AET

5-MeO-AET
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name 1-(5-methoxy-1H-indol-3-yl)butan-2-amine;
CAS Number	4765-10-0 ;
ChemSpider	21106244 ;
UNII	QCQ6JFX5NL;
CompTox Dashboard (EPA)	DTXSID20894761 ;
Chemical and physical data
Formula	C13H18N2O
Molar mass	218.300 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	201 to 203 °C (394 to 397 °F)
	SMILES CCC(N)Cc2c[nH]c1ccc(cc12)OC;
	InChI InChI=1S/C13H18N2O/c1-3-10(14)6-9-8-15-13-5-4-11(16-2)7-12(9)13/h4-5,7-8,10,15H,3,6,14H2,1-2H3 ; Key:JHTPCKWBFLMJMQ-UHFFFAOYSA-N ;
	(what is this?) (verify)

5-Methoxy-alpha-ethyltryptamine (5-MeO-α-ET) is a psychoactive drug and member of the tryptamine chemical class. It produces psychedelic and stimulant effects.^[1]

Dosage

5-MeO-α-ET, when used recreationally, is usually taken orally at dosages of 50–75 mg.

Effects

5-MeO-α-ET produces entactogenic and stimulant effects that can last 4–6 hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dosage and effects can be expected.

Dangers

There have been no reported deaths or hospitalizations from 5-MeO-α-ET, but its safety profile is unknown.

Legality

5-MeO-α-ET is unscheduled and uncontrolled in the United States, but possession and sales of 5-MeO-α-ET could be prosecuted under the Federal Analog Act because of its structural similarities to α-ET and α-MT.

References

^ Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2). Elsevier BV: 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. S2CID 22296279.

[Deluca_2012-1] Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 39 (2). Elsevier BV: 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. S2CID 22296279.

[1]